Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
At ASM Microbe 2026, Bruker Corporation’s (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604057503/en/ MALDI Biotyper® sirius CA System, delivering high‑throughput microbial identification to support efficient clinical laboratory workflows and improved diagnostic turnaround times
During the ASM 2026 meeting, Bruker showcases the expanded clinical capabilities of the MALDI Biotyper® CA System enabled by FDA Claims 7 and 8, supporting broader and more confident microbial identification in clinical laboratories. These enhancements include the MBT Compass® HT CA software, MBT FAST™ Shuttle US IVD, and an expanded FDA-cleared reference library covering 549 clinically validated microbial species across bacteria, anaerobes, and yeasts.
Bruker also highlights its focus on bloodstream infection and sepsis diagnostics, with a new vision to advance rapid antimicrobial susceptibility testing (AST) in clinical microbiology. Together with the MALDI Biotyper® CA System and the Bruker Arc™ automated sample preparation solution for positive blood cultures, this innovative rapid AST workflow under development is expected to enable faster, actionable diagnostics to support earlier clinical decision-making in critically ill patients.
